Cargando…

Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()

AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yiping, Li, Liming, Zhang, Qiuli, Clarke, Robert, Chen, Junshi, Guo, Yu, Bian, Zheng, Pan, Xianhai, Peto, Richard, Tao, Ran, Shi, Kunxiang, Collins, Rory, Ma, Liangcai, Sun, Huarong, Chen, Zhengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991854/
https://www.ncbi.nlm.nih.gov/pubmed/24461961
http://dx.doi.org/10.1016/j.ijcard.2013.12.065
_version_ 1782312509292675072
author Chen, Yiping
Li, Liming
Zhang, Qiuli
Clarke, Robert
Chen, Junshi
Guo, Yu
Bian, Zheng
Pan, Xianhai
Peto, Richard
Tao, Ran
Shi, Kunxiang
Collins, Rory
Ma, Liangcai
Sun, Huarong
Chen, Zhengming
author_facet Chen, Yiping
Li, Liming
Zhang, Qiuli
Clarke, Robert
Chen, Junshi
Guo, Yu
Bian, Zheng
Pan, Xianhai
Peto, Richard
Tao, Ran
Shi, Kunxiang
Collins, Rory
Ma, Liangcai
Sun, Huarong
Chen, Zhengming
author_sort Chen, Yiping
collection PubMed
description AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Biobank (CKB) of 512,891 adults aged 30–79 years recruited from 1737 rural and urban communities in China. Information about doctor-diagnosed ischaemic heart disease (IHD) and stroke, and the use of medication for the secondary prevention of CVD events, were recorded by interview. Multivariate logistic regression was used to estimate odds ratios (ORs) for use of secondary preventive treatment, adjusting simultaneously for age, sex, area and education. Overall, 23,129 (4.5%) participants reported a history of CVD (3.0% IHD, 1.7% stroke). Among them, 35% reported current use of any of 6 classes of drug (anti-platelet, statins, diuretics, ACE-I, β-blockers or calcium-channel blockers) for the prevention of CVD events, with the rate of usage greater in those with older age, higher levels of income, education, BMI or blood pressure. The use of these agents was associated positively with history of diagnosed hypertension (OR 7.5; 95% confidence intervals: 7.08–8.06) and diabetes (1.40; 1.28–1.52) and inversely with self-rated health status, but there was no association with years since diagnosis. CONCLUSIONS: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD was routinely treated with any proven secondary preventive drugs. The treatment rates were correlated with the existence of other risk factors, in particular evidence of hypertension.
format Online
Article
Text
id pubmed-3991854
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-39918542014-04-23 Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people() Chen, Yiping Li, Liming Zhang, Qiuli Clarke, Robert Chen, Junshi Guo, Yu Bian, Zheng Pan, Xianhai Peto, Richard Tao, Ran Shi, Kunxiang Collins, Rory Ma, Liangcai Sun, Huarong Chen, Zhengming Int J Cardiol Article AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Biobank (CKB) of 512,891 adults aged 30–79 years recruited from 1737 rural and urban communities in China. Information about doctor-diagnosed ischaemic heart disease (IHD) and stroke, and the use of medication for the secondary prevention of CVD events, were recorded by interview. Multivariate logistic regression was used to estimate odds ratios (ORs) for use of secondary preventive treatment, adjusting simultaneously for age, sex, area and education. Overall, 23,129 (4.5%) participants reported a history of CVD (3.0% IHD, 1.7% stroke). Among them, 35% reported current use of any of 6 classes of drug (anti-platelet, statins, diuretics, ACE-I, β-blockers or calcium-channel blockers) for the prevention of CVD events, with the rate of usage greater in those with older age, higher levels of income, education, BMI or blood pressure. The use of these agents was associated positively with history of diagnosed hypertension (OR 7.5; 95% confidence intervals: 7.08–8.06) and diabetes (1.40; 1.28–1.52) and inversely with self-rated health status, but there was no association with years since diagnosis. CONCLUSIONS: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD was routinely treated with any proven secondary preventive drugs. The treatment rates were correlated with the existence of other risk factors, in particular evidence of hypertension. Elsevier 2014-03-01 /pmc/articles/PMC3991854/ /pubmed/24461961 http://dx.doi.org/10.1016/j.ijcard.2013.12.065 Text en © 2013 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Article
Chen, Yiping
Li, Liming
Zhang, Qiuli
Clarke, Robert
Chen, Junshi
Guo, Yu
Bian, Zheng
Pan, Xianhai
Peto, Richard
Tao, Ran
Shi, Kunxiang
Collins, Rory
Ma, Liangcai
Sun, Huarong
Chen, Zhengming
Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()
title Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()
title_full Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()
title_fullStr Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()
title_full_unstemmed Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()
title_short Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people()
title_sort use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of china: china kadoorie biobank study of 0.5 million people()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991854/
https://www.ncbi.nlm.nih.gov/pubmed/24461961
http://dx.doi.org/10.1016/j.ijcard.2013.12.065
work_keys_str_mv AT chenyiping useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT liliming useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT zhangqiuli useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT clarkerobert useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT chenjunshi useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT guoyu useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT bianzheng useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT panxianhai useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT petorichard useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT taoran useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT shikunxiang useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT collinsrory useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT maliangcai useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT sunhuarong useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT chenzhengming useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople
AT useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople